Biotechnology

Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge

July 11, 2023 7:00 AM

The Parkinson's disease market is expected to grow to $12.8 billion by 2028. LAS VEGAS, NV / ACCESSWIRE / July 11, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose...

Read more

Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

July 10, 2023 1:00 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 10, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specializing in the development of therapies aimed at slowing the degenerative processes associated with aging and improving functional outcomes in patients suffering from age-related diseases, including respiratory failure in patients affected by...

Read more

Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

July 7, 2023 5:55 PM

VANCOUVER, BC / ACCESSWIRE / July 7, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. ("Vocan"), has completed final steps of its research for its biosynthetic production system (the System) and has filed a patent under the Patent Cooperation Treaty (PCT) (the "Patent" or "Filing") for international...

Read more

Morphogenesis, Inc to Present at the Virtual Investor Summer Spotlight Series

July 6, 2023 12:00 PM

Live moderated video webcast on Tuesday, July 11th at 3:00 PM ET TAMPA, FL / ACCESSWIRE / July 6, 2023 / Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome primary and acquired resistance to current immunotherapies, today announced that Dr. James Bianco, Chief Executive Officer of Morphogenesis will...

Read more

NatureMetrics Adopts Sapio Science's No-Code LIMS/ELN Platform to Accelerate Environmental DNA Monitoring

July 6, 2023 6:00 AM

Sapio LIMS/ELN Provides NatureMetrics With a Configurable Workflow and Data Solution That Adapts as eDNA Technology Rapidly Evolves BALTIMORE, MD / ACCESSWIRE / July 6, 2023 / Sapio Sciences, the science-aware™ lab informatics platform, today announced that since recently launching in the EMEA geography, NatureMetrics, the nature intelligence technology company, has adopted Sapio's platform to power its use of eDNA surveys and sequencing to...

Read more

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

July 5, 2023 8:45 AM

Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic...

Read more

Adolore Biotherapeutics to Participate in the Virtual Investor Summer Spotlight Series

July 5, 2023 8:45 AM

Live moderated video webcast on Tuesday, July 11th at 4:00 PM ET DELRAY BEACH, FL / ACCESSWIRE / July 5, 2023 / Adolore Biotherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for pain, today announced that Roelof Rongen, CEO and Roy Levitt, MD, Founder and Executive Chairman of Adolore, will participate in the Virtual Investor Summer Spotlight Series on...

Read more

enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events

July 5, 2023 8:05 AM

57 patients enrolled to date in the SAVVE® study Full SAVVE enrollment expected by year-end July 13 - Company to participate in investor event to further discuss enrollment July 18 - KOL event with two SAVVE study Principal Investigators IRVINE, CA / ACCESSWIRE / July 5, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided an...

Read more

Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

July 3, 2023 1:30 AM

Result of Annual General Meeting LONDON, UK / ACCESSWIRE / July 3, 2023 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below. Proxy Voting Results Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast...

Read more

Biovica International AB - Annual Report for the Financial Year 2022/2023 Published

June 30, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 30, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Annual report for the financial year 2022/2023 for Biovica International AB is published today on our website. Biovica International AB - Financial reports Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay,...

Read more

Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.

June 29, 2023 9:30 AM

COLLEGE STATION, TX / ACCESSWIRE / June 29, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ:SAGA) ("Sagaliam") (together the "Parties") announced today they have agreed to an amendment to the executed non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), operating...

Read more

Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO

June 29, 2023 8:30 AM

FORT LAUDERDALE, FL / ACCESSWIRE / June 29, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Howard L. Golub, MD, PhD as its new Executive Vice President (EVP) and Chief Science Officer (CSO). Dr. Golub has a distinguished background as a highly innovative healthcare...

Read more

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

June 29, 2023 5:00 AM

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development. HEIDELBERG, GERMANY / ACCESSWIRE / June 29, 2023 / BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE). The end goal of this research project is to...

Read more

The Oligonucleotide Therapeutics Society is Pleased to Announce the 2023 Annual Meeting in Barcelona, Spain

June 28, 2023 11:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 28, 2023 / The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting. Anyone interested in oligonucleotide therapeutics is welcome to join the event, which will be held virtually and in person on Oct. 22-25, 2023, in Barcelona, Spain. OTS is an open, nonprofit forum that fosters academic and industry-based...

Read more

Infusense Awarded $1 Million NSF SBIR Grant to Advance Rapid Fentanyl Toxicity Test

June 28, 2023 9:00 AM

Novel technology platform for fentanyl quantification selected for Small Business Innovation Research funding from the National Science Foundation. NASHVILLE, TN / ACCESSWIRE / June 28, 2023 / Infusense Corporation, a Nashville-based medical device company, has been granted a $1 million Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). The funding will drive the development and FDA approval of...

Read more

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

June 28, 2023 7:55 AM

Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study was completed by the University of Toronto in...

Read more

Adolore Biotherapeutics Announces Launch of Social Media Channels

June 27, 2023 9:00 AM

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic pain DELRAY BEACH, FL / ACCESSWIRE / June 27, 2023 / Adolore Biotherapeutics, Inc. ("Adolore" or the "Company") a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for pain, today announced the launch of its new corporate social media channels. To stay up-to-date with Adolore's latest...

Read more

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

June 27, 2023 8:15 AM

TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial...

Read more

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

June 27, 2023 8:05 AM

Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual...

Read more

ProteinQure Inc. Announces Robust Preclinical Efficacy in a Triple Negative Breast Cancer Mouse Tumour Model Study

June 26, 2023 11:10 AM

TORONTO, ON / ACCESSWIRE / June 26, 2023 / ProteinQure, a biopharmaceutical company pioneering the discovery and development of computationally-designed peptide therapeutics, is presenting at the 28th annual American Peptide Symposium exciting in vivo efficacy results from a de novo designed tumour-targeting peptide-drug conjugate (PDC). These findings address a major shortcoming of cytotoxic agents used in traditional chemotherapy treatments:...

Read more